Nanoemulsified Butenafine for Enhanced Performance against Experimental Cutaneous Leishmaniasis

Figure 1

BALB/c mice were treated topically with butenafine chloride formulated in the self-nanoemulsifying drug delivery system (SNEDDS) or in a SNEDDS-based nanogel (SNEDDS gel) containing butenafine (10 mg of butenafine per dose), butenafine solubilized in DMSO (10 mg/dose), and blank formulations of the nanosystems or intralesionally treated with Glucantime (100 mg/kg/dose) once a day during 15 days. Forty-eight hours after the last dose, fragments of the skin from BALB/c mice were collected and analyzed by histology. Histological section of the skin from (a) nontreated animals, (b) blank SNEDDS, (c) blank SNEDDS gel, (d) BUT-SNEDDS, (e) BUT-SNEDDS gel, (f) butenafine, and (g) Glucantime. White arrow shows an area of inflammatory infiltrate.

(a)

(b)

(c)

(d)

(e)

(f)

(g)